Compare Cassava Sciences Inc (FLNA) vs ArcelorMittal SA (MT) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

ArcelorMittal (MT) trades at $66.99, up 1.62% today, with strong technical momentum and bullish moving average signals. The company has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.17. Revenue declined from $79.8B in 2022 to $61.4B in 2025, but net income improved to $3.2B, reflecting margin expansion. Recent developments include a strategic AI collaboration with AWS and ongoing share buybacks.

The outlook remains positive with analyst consensus favoring Buy ratings (50%), though risks include declining revenue trends and heavy capital expenditures. The stock's valuation appears reasonable with P/E of 17.7 and P/B of 0.92, trading below book value. Key catalysts include steel import controls in Europe and expansion projects, while headwinds involve China weakness and decarbonization costs.